Clinical trial
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
NCT02603809
Study timeline
Study start (actual)2015-12-14Date precision: day
Registry last updated2022-11-23
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Essential Hypertensionunresolved
Interventions
Lisinopril 20 mgDRUG · verified · RxNorm: lisinopril 20 MG
PlaceboDRUG
Sponsors & collaborators
Idorsia Pharmaceuticals Ltd.lead sponsor
Mapped research locations
TucsonArizona, United States3MiamiFlorida, United States2TorontoOntario, Canada2San AntonioTexas, United States2AustinTexas, United States2New OrleansLouisiana, United States2WichitaKansas, United States2Los AngelesCalifornia, United States1CincinnatiOhio, United States1San DiegoCalifornia, United States1ColumbusOhio, United States1MontrealQuebec, Canada1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02603809 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.